ABNX — Abionyx Pharma SA Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | 0.17 | n/a | n/a | n/a | 0.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Directors
- Emmanuel Huynh
- Cyrille Tupin CEO
- Constance Keyserling
- Emmanuel de Fougeroux
- Ronald Barbaras
- Renee Benghozi
- Shawn Benoit
- Nathalie Sabina
- Gavin Sy
- Christian Chavy (66)
- Johan Christenson (62)
- Jean-Louis Dasseux DRC (60)
- Denis Lucquin
- Olivier Martinez
- Marc Riviere
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- March 24th, 2005
- Public Since
- March 30th, 2015
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 24,396,085
- Address
- Bat. D 33-43 Avenue Georges Pompidou, BALMA, 31130
- Web
- https://www.abionyx.com/en/
- Phone
- +33 562249706
- Auditors
- Deloitte & Associes
Latest News for ABNX
Upcoming events for ABNX
Similar to ABNX
ADOCIA ORD
Euronext - Paris
BIOPHYTIS ORD
Euronext - Paris
ERYTECH PHARMA ORD
Euronext - Paris
GENSIGHT BIOLOGICS ORD
Euronext - Paris
INVENTIVA ORD
Euronext - Paris
FAQ
As of Today at 19:54 UTC, shares in Abionyx Pharma SA are trading at €1.07. This share price information is delayed by 15 minutes.
Shares in Abionyx Pharma SA last closed at €1.07 and the price had moved by +18.14% over the past 365 days. In terms of relative price strength the Abionyx Pharma SA share price has underperformed the FTSE Global All Cap Index by -8.27% over the past year.
The overall consensus recommendation for Abionyx Pharma SA is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Abionyx Pharma SA does not currently pay a dividend.
Abionyx Pharma SA does not currently pay a dividend.
Abionyx Pharma SA does not currently pay a dividend.
To buy shares in Abionyx Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.07, shares in Abionyx Pharma SA had a market capitalisation of €26.06m.
Here are the trading details for Abionyx Pharma SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ABNX
Based on an overall assessment of its quality, value and momentum Abionyx Pharma SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abionyx Pharma SA is €2.05. That is 91.95% above the last closing price of €1.07.
Analysts covering Abionyx Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.18 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abionyx Pharma SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +6.4%.
As of the last closing price of €1.07, shares in Abionyx Pharma SA were trading +6.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Abionyx Pharma SA.
Abionyx Pharma SA's management team is headed by:
- Emmanuel Huynh -
- Cyrille Tupin - CEO
- Constance Keyserling -
- Emmanuel de Fougeroux -
- Ronald Barbaras -
- Renee Benghozi -
- Shawn Benoit -
- Nathalie Sabina -
- Gavin Sy -
- Christian Chavy -
- Johan Christenson -
- Jean-Louis Dasseux - DRC
- Denis Lucquin -
- Olivier Martinez -
- Marc Riviere -
We do not have data on Abionyx Pharma SA's shareholders